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Abstract
Aims The purpose of the current study was to investigate
the characteristic expression of circular RNAs (circRNAs)
in the peripheral blood of type 2 diabetes mellitus (T2DM)
patients and their potential as diagnostic biomarkers for
pre-diabetes and T2DM.
Methods CircRNAs in the peripheral blood from six
healthy individuals and six T2DM patients were collected
for microarray analysis, and an independent cohort study
consisting of 20 normal cases, 20 pre-diabetes patients and
20 T2DM patients was conducted to verify the five chosen
circRNAs. We then tested hsa_circ_0054633 in a third
cohort (control group, n = 60; pre-diabetes group, n = 63;
and T2DM group, n = 64) by quantitative real-time poly-
merase chain reaction (Q-PCR).
Results In total, 489 circRNAs were discovered to be dif-
ferentially expressed between the two groups, and of these,
78 were upregulated and 411 were downregulated in the
T2DM group. Five circRNAs were then selected as candi-
date biomarkers and further verified in a second cohort.
Hsa_circ_0054633 was found to have the largest area under
the curve (AUC). The diagnostic capacity of hsa_
circ_0054633 was tested in a third cohort. After introducing
the risk factors of T2DM, the hsa_circ_0054633 AUCs for
the diagnosis of pre-diabetes and T2DM slightly increased
from 0.751 (95% confidence interval [0.666–0.835],
P\ 0.001) to 0.841 ([0.773–0.910], P\ 0.001) and from
0.793 ([0.716–0.871], P\ 0.001) to 0.834 ([0.762–0.905],
P\ 0.001), respectively.
Conclusions Hsa_circ_0054633 presented a certain diag-
nostic capability for pre-diabetes and T2DM.
Keywords Circular RNAs (circRNAs)  Circulating
circRNA  Type 2 diabetes mellitus (T2DM)  Pre-
diabetes  Microarray analysis  Biomarker
Introduction
According to the International Diabetes Federation (IDF)
Diabetes Atlas (Seventh Edition, 2015), nearly 410 million
diabetic patients exist worldwide, 46.5% of whom have not
been diagnosed. By 2040, the number of patients with
diabetes may increase to 642 million [1]. In the advanced
stages of T2DM, patients often experience various com-
plications. Therefore, early diagnosis and intervention are
urgently needed. However, current diagnostic methods
show various insufficiencies for the early diagnosis of
T2DM. To improve this situation, researchers have asses-
sed the value of insulin resistance, b-cell function, insulin
sensitivity and fasting insulin for the diagnosis of T2DM
using the homeostasis model [2]. Some researchers have
attempted to identify new indicators of T2DM at early
stages, and others have explored the association between
genetic variants and early-onset T2DM [3, 4], a new and
highly sensitive biomarker that will be of great value.
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In recent years, with advancements in genomics, the
single-nucleotide polymorphism (SNP) sites of related
encoding sequences of some complicated diseases,
including T2DM, have been gradually uncovered [5, 6].
Researchers have found that the human genome can be
widely transcribed into a large number of non-coding
RNAs that are closely linked to the occurrence and
development of diseases [7]. CircRNAs are a type of closed
circular non-coding RNAs, formed by an exon, an intron,
or the reverse splicing of the two [8, 9]. Intracellular cir-
cRNAs have higher biological stability than most linear
RNAs because of their resistance to RNA exonucleases
[10, 11]. CircRNAs have multiple regulatory mechanisms
of gene expression [12]: Some circRNAs can be used as
microRNA (miRNA) sponges, playing a role in posttran-
scriptional regulation by engaging in competitive combi-
nation with miRNA [13]. CircRNAs can also regulate
transcription by interacting with small nuclear RNA
(snRNA) or RNA polymerase II in the nucleus [14] and can
competitively regulate RNA splicing by binding to tran-
scription factors [15]. Substantial amounts of circRNAs are
widely distributed in the cytoplasm and nucleus [16].
CircRNAs play important roles in various diseases,
including cancer, atherosclerosis, osteoarthritis, pulmonary
fibrosis, myotonic dystrophy and Alzheimer’s disease
[17–20]. The high biological stability of circRNAs is a pre-
condition for their usage as biomarkers for various diseases.
For example, Li et al. [21] found that hsa_circ_002059 could
be used as a new biomarker for gastric cancer, Zhang et al.
[22] determined that circ-ITCH could be used for the clinical
diagnosis of esophageal cancer, and Qin et al. [23] discov-
ered that hsa_circ_0005075 could be used as a potential
biomarker for hepatocellular carcinoma. Regarding dia-
betes, cerebellar degeneration-related autoantigen 1 (CDR1)
is a protein coding gene located in Xq27.1. As the natural
antisense transcripts of CDR1, circRNA-CDR1 has been
found to affect insulin secretion and b cell renewal [24]. In
this study, we compared the expression profile of circRNAs
in the peripheral blood of T2DM patients and matched
control subjects by microarray analysis and then confirmed
our findings in larger independent cohorts. The results
demonstrated that hsa_circ_0054633 is a sensitive and
specific biomarker for pre-diabetes and T2DM diagnosis.
Materials and methods
Study population
In this study, a total of 259 individualswere classified into three
cohorts (their clinical and demographic characteristics are
presented inSupplementaryTables 1–3).Theparticipantswere
enrolled from among the outpatients and inpatients of the
cardiology and endocrinology departments of the People’s
Hospital ofZhengzhouUniversity fromJuly2015 to June2016.
Subjects with any of the following characteristics were exclu-
ded: (i)malignancies, (ii) liver and kidney dysfunction, (iii) any
other clinically systemic acute or chronic inflammatory dis-
ease(s), (iv) autoimmune disease, (v) untreated hypertension,
and (vi) any endocrine disease other than T2DM.
Study process
The process of this study is shown in Fig. 1 Each study subject
was tested using the oral glucose tolerance test (OGTT) to
determine whether they were healthy or had pre-diabetes or
T2DM. Six control individuals and six T2DM patients were
selected to donate venous blood samples, and total RNA was
extracted formicroarray analysis. The screened circRNAswere
thenvalidated in an independent cohort (control group,n = 20;
pre-diabetes group, n = 20; and T2DM group, n = 20). After
receiver operating characteristic (ROC) curve analysis, the
circRNA with the best diagnostic value was selected as the
biomarker, and its diagnostic value was validated in another
independent cohort (control group,n = 60; pre-diabetes group,
n = 63; and T2DM group, n = 64).
The definitions of pre-diabetes and T2DM
and collection of whole blood samples
In this study, pre-diabetes and T2DM were diagnosed
according to the 1998 Standards of the World Health
Organization (WHO) [25]. Thus, patients meeting either of
the following criteria could be diagnosed as having T2DM:
(i) fasting plasma glucose (FPG) C 125 mg/dL (7.0 mmol/
L), where fasting is defined as no caloric intake for at least
8 h or (ii) two-hour post-load plasma glucose C200 mg/dL
(11.1 mmol/L) during an OGTT.
Additionally, patients meeting either of the following
standards were diagnosed as having pre-diabetes: (i) FPG
C110 mg/dL (6.1 mmol/L) and \125 mg/dL (7.0 mmol/
L); or (ii) two-hour post-load plasma glucose C140 mg/dL
(7.8 mmol/L) and\200 mg/dL (11.1 mmol/L) during an
OGTT.
Blood sample collection was performed as follows:
After overnight fasting, 2 mL of blood was collected from
the median cubital vein of each patient before breakfast
and then stored in ethylenediaminetetraacetic acid (EDTA)
anticoagulant vacutainers. The total RNA was then
extracted as soon as possible.
RNA extraction and Q-PCR
A fast total RNA extraction kit (Biotech, Beijing, China)
was used to extract total RNA from 1 mL of whole blood
according to the manufacturer’s instructions. RNA was
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then dissolved in RNase-free water. The yield and purity
were measured by a NanoDrop 2000 instrument (Thermo
Scientific, Waltham, MA, USA). The integrity of the RNA
was determined by 1% formaldehyde denaturing gel elec-
trophoresis. A PrimeScript RT Reagent Kit (Takara Bio,
Nojihigashi, Kusatsu, Japan) was used for the production of
complementary DNA (cDNA) by reverse transcription,
according to the manufacturer’s instructions. Q-PCR was
performed using SYBR-Green Premix Ex Taq (Takara Bio,
Nojihigashi, Kusatsu, Japan) and monitored by an ABI
PRISM 7500 Sequence Detection System (Applied
Biosystems, Life Technologies, Waltham, MA, USA). The
relative expression levels of circRNAs were determined via
Q-PCR. The sequences of the primers used in the Q-PCR
assay are shown in Supplementary Table 4.
CircRNA microarray analysis
The RNAs of the peripheral blood of six control subjects
and six T2DM patients were extracted for microarray
analysis. The purity and concentration of the RNA were
determined by a NanoDrop ND-1000 instrument (Thermo
Scientific, Waltham, MA, USA). The integrity of the RNA
was evaluated using a Bioanalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA, USA). The extracted RNAs
were digested, dephosphorylated, denatured, amplified and
labeled with Cy3-dCTP according to the manufacturer’s
specifications. The purified RNAs were hybridized to a
microarray (Agilent human circRNA Array V2.0) con-
taining 170,340 human circRNA probes. The microarray
data of the circRNAs were then analyzed using GeneSpring
software V13.0 (Agilent Technologies, Santa Clara, CA,
USA). The thresholds were as follows: fold change, C2 or
B-2; P\ 0.05 according to the t test.
Data analysis
Variables with different distributions were expressed as
means ± standard deviations, medians (quartiles) or per-
centages when they fit. In the scatterplot of circRNA
Fig. 1 Study flow
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expression, the horizontal lines represent the median val-
ues. The Chi-square test was used for categorical variables,
whereas the Kolmogorov–Smirnov and Shapiro–Wilk tests
were performed to check data normality for continuous
variables, followed by the test for homogeneity of vari-
ances. The clinical and demographic indicators were
checked for significant differences by one-way analysis of
variance (ANOVA), if the continuous variables were con-
sistent with the normal distribution and homogeneity of
variance; if not, the Kruskal–Wallis H test was used. The
clinical diagnostic value of a given circRNA was verified
by ROC curve analysis, and when the AUC was equal to
0.5, the circRNA was defined as having no diagnostic
value. Furthermore, logistic regression analysis was per-
formed to obtain an odds ratio (OR) when the relative
expression of circRNAs was expanded by ten times.
P\ 0.05 was considered statistically significant. All sta-
tistical analyses were conducted using SPSS 22.0 (SPSS
Inc., Chicago, IL, USA).
Results
Expression profiles of circRNAs in the peripheral
blood of diabetic patients
To investigate the expression profiles of circRNAs in
healthy individuals and T2DM patients, six healthy sub-
jects and six T2DM patients were selected. Microarray
analysis of the expression profiles of circRNAs in
peripheral blood was performed using the Agilent human
circRNA Array (V2.0). The results showed clear differ-
ences in the expression profiles of circRNAs between the
two groups (Fig. 2). Differential expression was detected in
a total of 489 circRNAs; of these, 78 were upregulated and
411 were downregulated in the T2DM group (Supple-
mentary Table 5). To obtain the biomarkers that would be
most applicable in clinical practice, the candidate
biomarkers were selected from the 78 upregulated cir-
cRNAs utilizing stricter screening criteria: fold change
[2.4 and P\ 0.01. Five circRNAs met these standards:
hsa_circ_0068087, hsa_circ_0054633, hsa_circ_0124636,
hsa_circ_0139110 and hsa_circ_0018508 (highlighted in
Supplementary Table 5). These circRNAs were used as
candidate biomarkers in a subsequent validation utilizing a
larger cohort.
The expression profile of circRNAs verified
by Q-PCR
To validate the five selected candidate circRNAs, Q-PCR
was conducted in an independent cohort (control group,
n = 20; pre-diabetes group, n = 20; and T2DM group,
n = 20). The results are shown in Fig. 3. The levels of
hsa_circ_0124636 and hsa_circ_0139110 expression
among the three groups presented no significant differ-
ences. The levels of hsa_circ_0018508 expression in the
pre-diabetes and T2DM groups did not differ, but both
were higher than that of the control group. The expression
levels of hsa_circ_0054633 and hsa_circ_0068087 were
Fig. 2 Heat map of the
circRNA microarray profiles in
control individuals and T2DM
patients. The expression of
circRNAs is hierarchically
clustered on the y-axis, and
blood samples are hierarchically
clustered on the x-axis. The
expression levels are presented
in red and green, which indicate
upregulated and downregulated
circRNAs, respectively.
Numbers marked with A and B
are from control individuals and
T2DM patients, respectively
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Fig. 3 Expression levels of the
selected circRNAs quantified by
Q-PCR. a, b and c show the




d, f present the ROC curve
analyses of hsa_circ_0054633
and hsa_circ_0068087 for the
diagnosis of pre-diabetes; e,
g are the ROC curve analyses of
hsa_circ_0054633 and
hsa_circ_0068087 for the
diagnosis of T2DM. The AUC
values are given on the graphs
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significantly different among the three groups and
increased gradually from the control group to the pre-dia-
betes group to the T2DM group.
ROC curve analysis of circRNAs with differential
expression
To determine the diagnostic values of hsa_circ_0054633 and
hsa_circ_0068087 for pre-diabetes and T2DM, ROC curve
analysis was performed (Fig. 3). The AUCs of hsa_circ_
0054633 for the diagnosis of pre-diabetes and T2DM were
0.747 ([0.589–0.906], P = 0.007) and 0.72 ([0.562–0.878],
P = 0.017), respectively. The AUCs of hsa_circ_0068087 for
the diagnosis of pre-diabetes and T2DM were 0.692
([0.529–0.856], P = 0.037) and 0.717 ([0.557–0.878],
P = 0.019); the sensitivity and specificity are shown in
Table 1. Because hsa_circ_0054633 showed higher AUC and
lower P values than hsa_circ_0068087, the former was chosen
as the diagnostic biomarker for pre-diabetes and T2DM.
Further clinical validation of the biomarker
To verify its clinical diagnostic capability, hsa_circ_0054633
was tested in another cohort (control group, n = 60; pre-dia-
betes group, n = 63; and T2DM group, n = 64). The results
are shown in Fig. 4. The level of hsa_circ_0054633 expression
increased gradually from the control group to the pre-diabetes
group to theT2DMgroup,with a fold changeof1.8between the
first twogroups and1.7 between the latter twogroups.Then, the
ROC curve analysis was performed.When used as a biomarker
for the diagnosis of pre-diabetes and T2DM, the AUC,
threshold, sensitivity and specificity of hsa_circ_0054633were
0.751 ([0.666–0.835], P\0.001), 0.103, 0.905 and 0.483,
respectively, and 0.793 ([0.716–0.871], P\0.001), 0.270,
0.719 and 0.778, respectively. The crude ORs were 3.05
([1.803–5.159], P\0.001) and 2.056 ([1.530–2.762],
P\0.001), respectively. After introducing the risk factors of
T2DM (smoking, hypertension, body mass index [BMI], total
cholesterol [TC], triglycerides [TG], high-density lipoprotein
[HDL] and low-density lipoprotein [LDL]), the AUCs
increased to 0.841 ([0.773–0.910], P\0.001) with a sensi-
tivity of 0.778 and a specificity of 0.783 and 0.834
([0.762–0.905], P\0.001) with a sensitivity of 0.766 and a
specificity of 0.794, respectively. The adjustedORswere 6.797
([3.025–15.273], P\0.001) and 2.769 ([1.881–4.077],
P\0.001), respectively.
Biomarker expression levels in different gender
and age groups
To investigate the levels of hsa_circ_0054633 expression
in different gender and age groups, the three groups of the
third cohort were divided according to age (cut-off:
50 years old) and gender. The results are shown in Table 2
and indicate that no differential expression of hsa_
circ_0054633 was identified between the different gender
and age groups.
Discussion
The high morbidity of T2DM and its various complications
severely threaten human health. In the advanced stages of
T2DM, patients often experience various complications,
which severely impact their quality of life. Multiple large-
scale investigations have revealed that intensive glucose-
lowing therapy in the early phases of T2DM can benefit
patients substantially, reducing the incidences of
macrovascular and microvascular complications [26, 27].
However, in the early stages of T2DM, most patients are
asymptomatic, and they rarely visit hospitals to seek
diagnosis and therapy.
Current diagnostic methods have various deficiencies
for the early diagnosis of T2DM: OGTT is the gold stan-
dard for diagnosing T2DM. However, because this proce-
dure is time-consuming and complicated, it is only
considered when there is a strong suspicion that a patient
has T2DM. FPG is convenient, but the rate of missed
diagnoses is high [28]. Finally, hemoglobin A1c (HbA1c)
test has not been standardized in Chinese hospitals.
Therefore, a convenient, highly specific and sensitive
diagnostic method is urgently needed to facilitate the early
diagnosis of T2DM.
Because of their convenience of sampling and low cost,
hematological markers play an important role in the diag-
nosis of many diseases. One of the most important func-
tions of circRNAs is their role as ‘‘miRNA sponges,’’
which competitively bind miRNAs to generate post-tran-
scriptional regulation. Long non-coding RNAs (lncRNAs)
can also interact with miRNAs to regulate gene translation,
suggesting a potential correlation among the three types of
non-coding RNAs [29]. Some lncRNAs and miRNAs have
been demonstrated to be involved in the occurrence and
development of T2DM; furthermore, they can be used as
biomarkers for T2DM diagnosis [30, 31]. CircRNAs are
much more stable than linear RNAs in cells, and in some
tissues, their expression levels are ten times higher [10];
thus, circRNAs make better biomarkers.
The current study revealed significant differences
between the expression levels of circRNAs in the periph-
eral blood of T2DM patients and that of healthy subjects.
To reduce the interference of factors other than T2DM to
the minimum, we strictly matched the demographic and
clinical characteristics (especially the hematological indi-
cators, such as the blood cell count and percentage of white
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blood cells) of the first cohort. But individual differences
among the patients were huge; the differential expression
of circRNA might be attributed to changes in the activation
states of different blood cell types. Therefore, we selected
the five circRNAs with the most significant differences as
candidate biomarkers. Hsa_circ_0054633 showed the
highest diagnostic value for pre-diabetes and T2DM among
the five candidate biomarkers and was further verified in
another cohort. It continued to have reliable diagnostic
value, suggesting that hsa_circ_0054633 has the potential
to be used as a diagnostic biomarker for pre-diabetes and
T2DM in clinical practice.
The field of circRNAs is quite new, and thus, to the best
of our knowledge, no definite evidence demonstrating the
Table 1 Validation of the
selected circRNAs by Q-PCR
CircRNA AUC 95% CI P value Sensitivity Specificity Fold change
hsa_circ_0054633
Pre-diabetes 0.747 0.589–0.906 0.007 0.75 0.70 1.7
T2DM 0.720 0.562–0.878 0.017 0.55 0.85 1.8
hsa_circ_0068087
Pre-diabetes 0.692 0.529–0.856 0.037 0.80 0.50 1.8
T2DM 0.717 0.557–0.878 0.019 0.90 0.50 1.6




control, pre-diabetes and T2DM
groups. *P\ 0.05. b, c present
the ROC curve analyses of
hsa_circ_0054633 and
hsa_circ_0054633 ? risk
factors for the diagnosis of
pre-diabetes and T2DM,
respectively
Acta Diabetol (2017) 54:237–245 243
123
functions of hsa_circ_0054633 is available. The results of
gene ontology (GO) analysis revealed that hsa_-
circ_0054633 not only participates in biological processes,
such as cell cycle and mitotic cell cycle arrest, but is
strongly correlated with molecular catabolism. The cell
cycle is the basic process of cellular life activities. The
proliferation of b cells is regulated by cell cycle progress,
and decreased b cell proliferation is the major cause of
insufficient insulin secretion [32], which is the basic
characteristic of T2DM. Besides, T2DM is a chronic
metabolic disease characterized by disordered carbohy-
drate, lipid and protein metabolism, and we hypothesize
that hsa_circ_0054633 may participate in the pathogenesis
of T2DM by influencing the cellular metabolism and cell
cycle.
To the best of our knowledge, this study is the first to
investigate the expression profiles of circRNAs in the
peripheral blood of patients with T2DM and to validate the
utility of hsa_circ_0054633 as a diagnostic biomarker for
pre-diabetes and T2DM. The biomarker identified in this
study (hsa_circ_0054633) can be easily tested using
peripheral blood. Furthermore, its relatively low cost and
high specificity and sensitivity make it a potentially highly
useful tool for the diagnosis of T2DM and pre-diabetes.
In the present study, only hsa_circ_0054633 was vali-
dated; thus, the expression profiles of other circRNAs in
T2DM and pre-diabetes patients remain to be explored.
Additionally, this was a single-center study, with a high
geographic concentration of subjects. Therefore, whether
populations in other regions exhibit similar circRNAs
expression profiles is unknown. Thus, the results of our
study require further verification in larger and more diverse
cohorts.
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